Xeris Biopharma Files 2024 Executive Compensation Details
Ticker: XERS · Form: DEF 14A · Filed: Apr 23, 2025 · CIK: 1867096
| Field | Detail |
|---|---|
| Company | Xeris Biopharma Holdings, Inc. (XERS) |
| Form Type | DEF 14A |
| Filed Date | Apr 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, governance
TL;DR
Xeris Biopharma dropped its 2024 exec pay details, check out Shannon & Edick's equity awards.
AI Summary
Xeris Biopharma Holdings, Inc. filed its DEF 14A on April 23, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to key personnel such as John P. Shannon and Paul R. Edick. It also provides historical compensation data for the years 2021 through 2023.
Why It Matters
This filing provides transparency into how Xeris Biopharma compensates its top executives, which can influence investor decisions and perceptions of company management.
Risk Assessment
Risk Level: medium — DEF 14A filings primarily concern executive compensation and corporate governance, which can indicate potential risks related to management decisions and shareholder alignment.
Key Numbers
- 2024 — Fiscal Year (Reporting period for executive compensation)
- 2021-2023 — Historical Data (Previous years' compensation information included)
Key Players & Entities
- Xeris Biopharma Holdings, Inc. (company) — Filer of the DEF 14A
- John P. Shannon (person) — Executive mentioned in compensation details
- Paul R. Edick (person) — Executive mentioned in compensation details
- 2024-12-31 (date) — Fiscal year end for compensation reporting
- 20250423 (date) — Filing date
FAQ
What was the total compensation for John P. Shannon in 2024?
The filing indicates equity awards granted to John P. Shannon for the fiscal year 2024, but specific total dollar amounts are not detailed in the provided snippet.
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used to solicit proxies from shareholders for an annual meeting and provides detailed information on executive compensation, director nominations, and other corporate governance matters.
When was this DEF 14A filing submitted?
The filing was submitted on April 23, 2025.
Which fiscal year does the primary compensation data in this filing cover?
The primary compensation data in this filing covers the fiscal year ending December 31, 2024.
Are there any specific dollar amounts mentioned for equity awards in the provided text?
The provided text mentions 'YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember' and 'EqtyAwrdsInSummryCompstnTblForAplblYrMember' for individuals like John P. Shannon and Paul R. Edick for the 2024 fiscal year, but the specific dollar values are not present in this snippet.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 23, 2025 by John P. Shannon regarding Xeris Biopharma Holdings, Inc. (XERS).